

KEYPAD Trial News

www.anzup.org.au

Welcome to the 6th KEYPAD study newsletter

Thank you to all the KEYPAD investigators and trial teams for your continued efforts throughout a difficult and turbulent 2020. So far KEYPAD has recruited a total of 39 patients. The study has just 31 more patients to recruit to reach our target recruitment of 70. Please consider promoting this trial and encourage cross-referral for suitable patients to support this important study.

A/Professor Craig Gedye, Study Chair

Site accrual

Four patients have been recruited to KEYPAD this year reaching a total of 39/70 patients. Many thanks to all site staff for their ongoing support in screening and recruiting patients during these difficult times. Please continue to discuss the study at MDTs and encourage colleagues to refer any eligible patients if and when possible. Please don't hesitate to contact the KEYPAD team for any eligibility or study questions: KEYPAD@ctc.usyd.edu.au.

Site Name	Participants to Date
St George Hospital	7
Concord Repatriation General Hospital	6
Calvary Mater Newcastle	5
Royal Brisbane & Women's Hospital	4
Sunshine Coast University Hospital	4
Flinders Medical Centre	3
Fiona Stanley Hospital	2
Ballarat Oncology and Haematology Services	2
Eastern Health / Box Hill	1
Northern Cancer Institute	1
Peter MacCallum Cancer Centre (closed)	1
ICON cancer Care Centre	1
Monash Health (Monash Medical Centre Clayton of Monash Health)	1
The Townsville Hospital	1
Border Medical Oncology	0
St Vincent's Hospital (Sydney)	In start-up
	39

What is KEYPAD?

Denosumab and Pembrolizumab in clear cell renal carcinoma: a phase II trial.

STUDY CHAIR

*A/Professor
Craig Gedye*



COVID-19 protocol deviations

Please continue to refer to the COVID-19 guidance document and report any protocol deviations as instructed. If a KEYPAD patient tests positive for COVID-19 please ensure prompt reporting to the CTC via email as well as on InForm. Any questions or assistance please contact the study team KEYPAD@ctc.usyd.edu.au.

Tissue blocks

1. Prior to registration, confirm availability of tissue block using the Tissue Availability Form (V3.1, 16-Dec-2019).
2. After registration, request block and ship to central lab as soon as possible.
3. If pathology decline to release block, **DO NOT CUT SLIDES** until requested by the KEYPAD team.

The AUTO-CHECK sub-study

AUTO-CHECK closed to new patient recruitment in Dec 2019. For existing KEYPAD patients, cease collection of AUTO-CHECK serial research bloods (shipped in real-time to ANU).

Note - continue collecting all other TR bloods from existing and future KEYPAD patients.

Data entry and site payments

Please update your patient records in InForm and resolve any data queries to ensure site and per-patient payments for the January – June cycle are made in full.

KEYPAD is a collaboration between ANZUP and NHMRC Clinical Trials Centre.



This investigator initiated ANZUP study has been supported both financially and with study drug by MSD and Amgen.



MSD



ANZUP is supported by the Australian Government through Cancer Australia.



Australian Government
Cancer Australia



Below the Belt
YOUR WAY



1 - 30 September 2020
www.belowthebelt.org.au/yourway

KEYPAD key contacts

- Clinical trial operations, CTC E: keypad@ctc.usyd.edu.au
- Coordinating PI: Craig Gedye E: craig.gedye@newcastle.edu.au
- Sponsor queries (payments, contracts) Nisha Rana E: trials@anzup.org.au
- Trial pages: <https://www.anzup.org.au/content.aspx?page=keypad>